References
- De Haan, L. Subjective experiences of patients with schizophrenia related to antipsychotic medication. In: L De Haan, editor. Patients’ perspectives, subjective experiences and attitudes of patients with recent onset schizophrenia. Thesis, University of Amsterdam, 2001. p. 105–14.
- Allan ER, Sison CE, Alpert M, et al. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Psychopharmacol Bull 1998; 34: 71–4
- Lambert M, Graf Schimmelmann B, Karo A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs – Concepts, measurement and clinical relevance. Pharmacopsychiat 2003; 36(Suppl 3)181–90
- Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationship to objective psychopathlogy, quality of life, compliance and other variables. Int Clin Psychopharmacol 1995; 10(Suppl 3)133–8
- Schimmelmann BG, Schacht M, Perro C, Lambert M. The initial dysphoric reaction (IDR) followed the first neuroleptic dosage. Nervenarzt 2004; 75: 36–43
- Karow, A, Czekalla, J, Mahl, C, et al. Subjective well-being under neuroleptic therapy: 6 month data from the Schizophrenia Outpatients Health Outcomes Study. AEP, 3rd European Conference on Psychotherapy, Heidelberg, 2003. p. 67.
- Helmchen H. Prediction of course and therapeutic response in psychiatric disease. Pharmacopsychiat 1983; 16: 173–4
- Kane JM, Leucht S, Carpenter D. Expert consensus guidelines for optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003; 64((Suppl))5–19
- Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76
- Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76–338. National Institut of Mental Health, Rockville, MD 1976
- American Psychiatric Association. Diagnostic Criteria from DSM-IV. American Psychiatric Press, Washington, DC 1994
- Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 334((Suppl))1–100
- Cabeza IG, Amador MS, Lopez CA, et al. Subjective response to antipsychotics in schizophrenic patients: Clinical implications and related factors. Schizophr Res 2000; 41: 349–55
- Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544–9
- Gervin M, Browne J, Garavan M, et al. Dysphoric subjective response to neuroleptics in schizophrenia: Relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999; 14: 405–9
- Prosser ES, Csernansky JF, Kaplan J, et al. Depression, parkinsonian symptoms and negative symptoms in schizophrenic treated with neuroleptics. J Nerv Ment Dis 1987; 175: 100–5
- Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 1997; 42: 255–64
- Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002; 57: 209–19